Company: CI
Filing Date: 2025-09-02
Form Type: S-3ASR
Source: 0001140361-25-033568
Chunk: 1

Company: Cigna Group
Filing Date: 2025-09-02
Form: S-3ASR
Chunk 1
---
 box. ☒ If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large accelerated filer ☒                                            |     | Accelerated filer☐         |
| Non-accelerated filer☐ (Do not check if a smaller reporting company) |     | Smaller reporting company☐ |
|                                                                      |     | Emerging growth company☐   |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

#### TABLE OF CONTENTS

### PROSPECTUS

#### The Cigna Group

#### Debt Securities

#### Common Stock

#### Preferred Stock

#### Warrants

#### Purchase Contracts

#### Units
**The Cigna Group may offer and sell the securities listed above from time to time in one or more classes or series and in amounts, at prices and on terms that we may determine at the time of the offering. We will provide the specific terms of the securities in supplements to this prospectus.

The debt securities, preferred stock, warrants and purchase contracts may be convertible into or exercisable or exchangeable for common or preferred stock or other securities of the Company or debt or equity securities of one or more other entities. These securities may also be sold by one or more selling security holders to be named in a prospectus supplement. You should read this prospectus and any related prospectus supplement carefully before you invest in our securities.

Our common stock is listed on the New York Stock Exchange (the “NYSE”) under the symbol “CI”. The last reported sale price of our common stock on the NYSE on August 29, 2025 was $300.87 per share.

We or any selling security holders may offer and sell these securities to or through one or more underwriters, dealers or agents, or